ClinicalTrials.gg
CompletedNCT00834639Updated Aug 20, 2009Results posted

Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions

A Phase 1 interventional study of divalproex sodium and Depakote® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-08-20.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will compare the relative bioavailability of 500 mg Divalproex Sodium Delayed-Release Tablets with that of 500 mg Depakote® Tablets following a single oral dose (1 x 500 mg tablets)in healthy subjects under fasting conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Screening Demographics: All subjects selected for this study will be healthy men or women 18-65 years of age, inclusive, at the time of dosing. The subject's (BMI) should be less than or equal to 30.
  • Screening Procedures: Each subject will complete the screening process within 28 days prior to period I dosing. Consent documents for both the screening evaluation and antibody determination will be reviewed, discussed and signed by each potential participant before full implementation of screening procedures.

Screening will include general observations, physical examination, demographics, medical and medication history, an , sitting blood pressure and heart rate, respiratory rate and temperature. The physical examination will include, but may not be limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems.

The screening clinical laboratory procedures will include:

  • HEMATOLOGY: hematocrit, , WBC count with differential, RBC count, count
  • CLINICAL CHEMISTRY: serum creatinine, BUN, glucose, (GOT), ALT(GPT), albumin, total , total protein, and alkaline phosphatase
  • HIV antibody, surface antigen, antibody screens
  • URINALYSIS: by dipstick; full microscopic examination if dipstick positive
  • URINE DRUG SCREEN: ethyl alcohol, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolites, opiates and phencyclidine
  • SERUM PREGNANCY SCREEN (female subjects only)
  • FOLLICLE STIMULATING HORMONE (FSH; female subjects only): verify status

If female and:

  • Is postmenopausal for at least 1 year with postmenopausal status defined as: > 60 years of age and amenorrheic for at least one year; if 60 years of age or younger, must also have a serum FSH level > 30 IU/L; or
  • Is surgically sterile for at least 6 months (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)

Exclusion criteria

Exclusion Criteria

  • Subjects with a recent history of drug or alcohol addiction or abuse.
  • Subjects with the presence of a disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigators).
  • Subjects whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.
  • Subjects demonstrating a positive surface antigen screen, a positive antibody screen, or a reactive antibody screen.
  • Subjects demonstrating a positive drug abuse screen when screened for this study.
  • Female subjects demonstrating a positive pregnancy screen.
  • Female subjects who are currently breastfeeding.
  • Subjects with a history of allergic response(s) to divalproex sodium or related drugs.
  • Subjects with a history of clinically significant allergies including drug allergies.
  • Subjects with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
  • Subjects who currently or report using tobacco products within 90 days of Period I dose administration.
  • Subjects who have taken any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period I dosing.
  • Subjects who report donating greater than 150 mL of blood within 28 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
  • Subjects who have donated plasma (e.g. plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study.
  • Subjects who report receiving any drug within 28 days prior to Period I dosing.
  • Subjects who report taking any systemic prescription medication in the 14 days prior to Period I dosing.
  • Subjects who report an intolerance of direct venipuncture.
  • Subjects who report consuming an abnormal diet during the 28 days prior to Period I dosing.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1

    Drug: divalproex sodium

  • Active comparator
    2

    Drug: Depakote®

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Observed Concentration)

    Bioequivalence based on Cmax.

    Time frame: Blood samples collected over a 72 hour period.

  2. AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Bioequivalence based on AUC0-t.

    Time frame: Blood samples collected over a 72 hour period.

  3. AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

    Bioequivalence based on AUC0-inf.

    Time frame: Blood samples collected over a 72 hour period.

07

Results

Posted Aug 4, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneDivalproex Sodium FirstDepakote® First
Started1212
Completed1212
Not completed00
Washout of 7 Days
Participant flow — Washout of 7 Days
MilestoneDivalproex Sodium FirstDepakote® First
Started1212
Completed1212
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneDivalproex Sodium FirstDepakote® First
Started1212
Completed1210
Not completed02
Withdrew: Physician decision02

Outcome measures

PrimaryCmax (Maximum Observed Concentration)

Bioequivalence based on Cmax.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · µg/mL
Cmax (Maximum Observed Concentration)
µg/mLDivalproex SodiumDepakote®
Cmax (Maximum Observed Concentration)53.89 ± 5.1555.19 ± 5.65
Statistical analysis
  • Divalproex Sodium vs Depakote® · Ratio of the t/r geometric mean x 100: 97.36 · 90% CI 93.68 to 101.18Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.
PrimaryAUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · µg*h/mL
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
µg*h/mLDivalproex SodiumDepakote®
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)905.18 ± 195.96898.24 ± 205.74
Statistical analysis
  • Divalproex Sodium vs Depakote® · Ratio of the t/r geometric mean x 100: 100.59 · 90% CI 97.07 to 104.24Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.
PrimaryAUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf.

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · µg*h/mL
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
µg*h/mLDivalproex SodiumDepakote®
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)982.25 ± 223.64978.75 ± 235.36
Statistical analysis
  • Divalproex Sodium vs Depakote® · Ratio of the t/r geometric mean x 100: 100.36 · 90% CI 97.35 to 103.46Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Divalproex Sodium FirstDepakote® FirstTotal
<=18 years000
Between 18 and 65 years121224
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Divalproex Sodium FirstDepakote® FirstTotal
Female011
Male121123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Divalproex Sodium FirstDepakote® FirstTotal
Black112
White111021
Hispanic011
Region of Enrollment
Region of Enrollment(participants)Divalproex Sodium FirstDepakote® FirstTotal
United States121224
08

Study locations

1 site
  • PRACS Institute, Ltd.
    Fargo, North Dakota 58104, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003, a primary completion of Sep 2003 and a completion of Sep 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 5 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2009
First posted
Feb 3, 2009
Start
Sep 2003
Primary completionActual
Sep 2003
CompletionActual
Sep 2003
Results first posted
Aug 4, 2009
Last update
Aug 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00834639
First posted
Feb 3, 2009
Start date
Sep 2003
Primary completion
Sep 2003
Completion
Sep 2003
Results posted
Aug 4, 2009
Last update
Aug 20, 2009

Study contacts

James D Carlson, Pharm. D.
principal investigator · PRACS Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion